AbbVie Inc. (0QCV.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
At close: 07:14PM BST
| Previous close | 146.95 |
| Open | 147.24 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 150.54 - 154.06 |
| 52-week range | 131.22 - 167.80 |
| Volume | |
| Avg. volume | 108,198 |
| Market cap | 219.147B |
| Beta (5Y monthly) | 0.62 |
| PE ratio (TTM) | 0.21 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
AbbVie (NYSE: ABBV) today announced that the European Commission has approved SKYRIZI® (risankizumab) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.3
- PR Newswire
AbbVie Reports Second-Quarter 2024 Financial Results
AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2024.
- PR Newswire
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Giant Cell Arteritis
AbbVie (NYSE: ABBV) today announced that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for upadacitinib (RINVOQ®; 15 mg, once daily) for the treatment of adult patients with giant cell arteritis (GCA).
© 2024 Yahoo. All rights reserved.